Mortality in incident haemodialysis patients: Time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2702-2710

  Fort, Joan ^a   Cuevas, Xavier ^b   García, Fernando ^c   Pérez García, Rafael ^d   Lladós, Fina ^e   Lozano, Javier ^e   Martín Malo, Alejandro ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Brain   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e Amgen SA   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

erythropoiesis stimulating agent dose; haemodialysis; haemoglobin; incident patients; mortality

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; HEMOGLOBIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL TRIAL; FUNCTIONAL STATUS; GROUPS BY AGE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; IRON DEFICIENCY ANEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; SURVIVAL RATE; VASCULAR ACCESS; ADOLESCENT; AGED; ANEMIA; BLOOD; CHRONIC DISEASE; COHORT ANALYSIS; DOSE RESPONSE; FOLLOW UP; KIDNEY DISEASES; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA; CHRONIC DISEASE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; LONGITUDINAL STUDIES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954781461     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq073     Document Type: Article

References (31)

1. Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 1989; 9: S30-S34
2. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 1999; 69: S35-S43
3. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
4. Chen HH, Tarng DC, Lee KF et al. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol 2008; 21: 543-549
5. Locatelli F, Pisoni RL, Akizawa T et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004; 44: 27-33
6. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14:1-50
7. NKF-DOQI clinical practice guidelines for the treatment ofanemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30: S192-S240
8. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003
9. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309-312
10. Strippoli GF, Tognoni G, Navaneethan SD et al. Haemoglobin targets: we were wrong, time to move on. Lancet 2007; 369: 346-350
11. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
12. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006; 47: 24-36
13. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
14. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
15. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
16. Yilmaz MI, Sonmez A, Saglam M et al. Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney Int 2009; 75: 1316-1321
17. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282
18. Cotter DJ, Stefanik K, Zhang Y et al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 2004; 57: 1086-1095
19. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am JKidney Dis 2004; 44: 866-876
20. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
21. Bradbury BD, Wang O, Critchlow CW et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70
22. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
23. Perez-Garcia R, Martin-Malo A, Fort J et al. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER-a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 2009; 24: 578-588
24. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haemato- crit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006; 4CD003967
25. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388
26. Kaysen GA, Muller HG, Ding J et al. Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 166
27. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083
28. Greene T. What did we learn from the HEMO Study? Implications of secondary analyses. Contrib Nephrol 2005; 149: 69-82
29. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736
30. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007; 22: 2129-2132
31. Gilbertson DT, Ebben JP, Foley RN et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138